Octeangin 2.6 mg – 20 Tablets
Octeangin 2.6mg 20 Tablets is a vascular-protective medicine used to improve blood circulation and reduce capillary fragility.
It is commonly prescribed in conditions related to venous and microcirculatory disorders.
Each tablet contains 2.6 mg calcium dobesilate monohydrate. Pack of 20 tablets.
🌱 What It Is
Octeangin contains octenidine dihydrochloride (2.6 mg per lozenge), an antiseptic and antimicrobial substance that helps fight bacteria and reduce throat irritation. It is used to relieve pain, soothe inflammation, and support healing in cases of sore throat, pharyngitis, or oral infections.
✅ Key Benefits
-
Relieves sore throat pain quickly and effectively.
-
Reduces inflammation of the throat and oral cavity.
-
Antimicrobial effect – helps fight bacteria and prevents infection.
-
Convenient lozenge form – easy to take anywhere, anytime.
💊 Use & Dosage
-
Adults and adolescents: 1 lozenge every 2–3 hours.
-
Maximum: up to 6 lozenges daily.
-
Allow the lozenge to dissolve slowly in the mouth.
-
Not suitable for children under 6 years.
⚠️ Safety & Precautions
-
For oral use only.
-
Do not exceed recommended daily dose.
-
Avoid if allergic to octenidine or any other ingredient.
-
If symptoms persist for more than 3 days, consult a doctor.
📦 Product Details
-
Form: Lozenges
-
Strength: 2.6 mg octenidine dihydrochloride per lozenge
-
Pack size: 20 lozenges
-
Indications: Sore throat, pharyngitis, oral irritation
🛒 Buy Octeangin 2.6 mg – 20 lozenges
Soothe sore throat pain and reduce inflammation with Octeangin lozenges—available now at zanzona.com with EU-wide delivery.
- Supports healthy blood vessels and circulation
- Helps reduce capillary fragility
- Convenient 20-tablet pack
Dosage: Adults – 1 tablet 2–3 times daily with meals, or as recommended by your doctor.
Always follow medical advice. Not suitable for children unless prescribed.
Store at room temperature, away from moisture and light.
Buy Octeangin 2.6mg 20 Tablets
Order Octeangin 2.6mg 20 Tablets

Reviews
There are no reviews yet.